Results 31 to 40 of about 327,068 (394)

Neutrophils and Asthma

Diagnostics, 2022
Although eosinophilic inflammation is characteristic of asthma pathogenesis, neutrophilic inflammation is also marked, and eosinophils and neutrophils can coexist in some cases. Based on the proportion of sputum cell differentiation, asthma is classified
Akira Yamasaki, Ryota Okazaki, Tomoya Harada   +2 more
doaj   +1 more source

Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – “first initiators” and “switchers”

Journal of Allergy and Clinical Immunology: In Practice, 2022
Simone Hashimoto, Johannes A. Kroes, Katrien Eger, Pearl Mau-Asam, Hendrik B. Hofstee, Sarah Bendien, Gert‐Jan Braunstahl, M.E.A.C. Broeders, Leonie M. Imming, Bas Langeveld, Anke H. Maitland‐van der Zee, Karen T.M. Oud, Kornelis W. Patberg, Frank W.J.M. Smeenk, Elisabeth APM Romme, Maarten Johannes van Bezouw, Marjo J. van de Ven, Anneke van Veen, Edwin van Velzen, Ilonka H. van Veen, Els J.M. Weersink, Anneke ten Brinke, Jacob K. Sont, EH Bel, R A P S O D I Team   +24 more
openalex   +3 more sources

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

The Egyptian Journal of Bronchology, 2022
Introduction Asthma is a heterogenous disease with various phenotypes that is characterized by airway limitation due to bronchospasm and airway inflammation associated with excessive mucus secretion.
Maged Mohamed Refaat, Riham Hazem Raafat, Heba Eid AbuAlia, Dina Sayed Sheha   +3 more
doaj   +1 more source

Targeting eosinophils: severe asthma and beyond [PDF]

Drugs in Context, 2019
Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market.
Caminati, Marco, Menzella, Francesco, Guidolin, Lucia, Senna, Gianenrico   +3 more
openaire   +5 more sources

PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study

Allergy, Asthma & Clinical Immunology, 2023
Background The prevalence of eosinophilic asthma in Lebanon, one of the most severe phenotypes among severe asthma, is not known. This study aimed at determining the prevalence of the eosinophilic phenotype defined as an eosinophil count ≥ 300 cells/mm3 ...
Wajdi Abi Saleh, Zuhair Alameh, Zeina Aoun Bacha, Joudy Bahous, Pierre Bou Khalil, Zahia Chahine, Hassan Chami, Georges Dabar, Hassan Dheiny, Alfred Dib, Dany farhat, Carla Irani, Georges Juvelekian, Nadim Kanj, Bassam Mansour, Moussa Riachi, Mirna Waked, Mohamad Yassine, Carole Youakim, Salah Zeinedine, Fares Zaitoun   +20 more
doaj   +1 more source

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

Frontiers in Pharmacology, 2021
Background: Severe eosinophilic asthma decreases lung function and causes worsen symptoms, often forcing recurrent maintenance corticosteroid use. The aim of our real-life study was to evaluate the effectiveness of an add-on treatment with benralizumab ...
Giulia Scioscia, Giulia Scioscia, Giovanna Elisiana Carpagnano, Carla Maria Irene Quarato, Carla Maria Irene Quarato, Donato Lacedonia, Donato Lacedonia, Sonia Santamaria, Sonia Santamaria, Piera Soccio, Annarita Depalo, Paolo Fuso, Paolo Fuso, Maria Pia Foschino Barbaro, Maria Pia Foschino Barbaro   +14 more
doaj   +1 more source

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Respiratory Research, 2023
Background The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects.
A. Vultaggio, M. Aliani, E. Altieri, P. Bracciale, L. Brussino, M. Caiaffa, P. Cameli, G. Canonica, C. Caruso, S. Centanni, M. D'Amato, F. De Michele, S. D. Del Giacco, F. Di Marco, F. Menzella, G. Pelaia, P. Rogliani, M. Romagnoli, Pietro Schino, G. Senna, Marco Benci, S. Boarino, J. Schroeder   +22 more
semanticscholar   +1 more source

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study

Journal of Clinical Medicine, 2023
Introduction: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking.
R. Campisi, S. Nolasco, C. Pelaia, P. Impellizzeri, M. D’Amato, Andrea Portacci, L. Ricciardi, G. Scioscia, N. Crimi, N. Scichilone, M. F. Foschino Barbaro, G. Pelaia, G. E. Carpagnano, A. Vatrella, C. Crimi   +14 more
semanticscholar   +1 more source

Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study

BMC Pulmonary Medicine, 2022
Background Eosinophilia is a significant factor in asthma severity; however, the prevalence of severe eosinophilic asthma in Saudi Arabia is largely unknown.
Hamdan Al-Jahdali, Siraj Wali, Amr S. Albanna, Riyad Allehebi, Hussein Al-Matar, Mohamed Fattouh, Maarten Beekman   +6 more
doaj   +1 more source

Severe asthma: adding new evidence – Latin American Thoracic Society

ERJ Open Research, 2021
This document constitutes a summary of the clinical practice guidelines (CPGs) prepared at the initiative of the Latin American Thoracic Society (ALAT). Due to new evidence in the treatment of severe asthma, it was agreed to select six clinical questions,
Gabriel García, Miguel Bergna, Juan C. Vásquez, Maria C. Cano Salas, José L. Miguel, Carlos Celis Preciado, Agustin Acuña Izcaray, Manuel Barros Monge, Natalia García Batista, Ignacio Zabert, José L. Mayorga, Renato Casanova Mendoza, Martha Gutierrez, Maria F. Montero Arias, Luzcenelia Urtecho Perez, Miguel Antúnez, Victoria Williams Derby, Alejandra Villatoro Azméquita, Luis Motiño, M. Alenita De Oliveira, Diana Rey Sanchez, Marisol Arroyo, Mario Rodriguez   +22 more
doaj   +1 more source